T. Poynard, J. Mchutchison, and M. Manns, Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C, Gastroenterology, vol.122, pp.1303-1313, 2002.

P. Marcellin, E. Gane, and M. Buti, Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label followup study, Lancet, vol.381, pp.468-475, 2013.

L. Falize, A. Guillygomarc'h, and M. Perrin, Reversibility of hepatic fibrosis in treated genetic hemochromatosis: A study of 36 cases, Hepatology, vol.44, pp.472-477, 2006.

L. W. Powell, J. L. Dixon, and G. A. Ramm, Screening for hemochromatosis in asymptomatic subjects with or without a family history, Arch Intern Med, vol.166, pp.294-301, 2006.

J. F. Dufour, R. Delellis, and M. M. Kaplan, Reversibility of hepatic fibrosis in autoimmune hepatitis, Annals of Internal Medicine, vol.127, pp.981-985, 1997.

M. M. Kaplan, R. A. Delellis, and H. J. Wolfe, Sustained biochemical and histologic remission of primary biliary cirrhosis in response to medical treatment, Annals of Internal Medicine, vol.126, pp.682-688, 1997.

G. Lassailly, R. Caiazzo, and D. Buob, Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients, Gastroenterology, vol.149, pp.379-88, 2015.

I. R. Wanless, E. Nakashima, and M. Sherman, Regression of human cirrhosis. Morphologic features and the genesis of incomplete septal cirrhosis, Arch Pathol Lab Med, vol.124, pp.1599-607, 2000.

E. L. Ellis and D. A. Mann, Clinical evidence for the regression of liver fibrosis, Journal of Hepatology, vol.56, pp.1171-1180, 2012.

M. Beaton, D. Guyader, and Y. Deugnier, Noninvasive prediction of cirrhosis in C282Y-linked hemochromatosis, Hepatology, vol.36, pp.673-681, 2002.

K. J. Allen, L. C. Gurrin, and C. C. Constantine, Iron-overload-related disease in HFE hereditary hemochromatosis, N Engl J Med, vol.358, pp.221-251, 2008.

E. Bardou-jacquet, J. Morcet, and G. Manet, Decreased cardiovascular and extrahepatic cancer-related mortality in treated patients with mild HFE hemochromatosis, J Hepatol, vol.62, pp.682-691, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01091479

N. Milman, P. Pedersen, and T. Steig, Clinically overt hereditary hemochromatosis in Denmark 1948-1985: epidemiology, factors of significance for long-term survival, and causes of death in 179 patients, Ann Hematol, vol.80, pp.737-781, 2001.

A. Bomford and R. Williams, Long term results of venesection therapy in idiopathic haemochromatosis, Q J Med, vol.45, pp.611-634, 1976.

C. Niederau, R. Fischer, and A. Pürschel, Long-term survival in patients with hereditary hemochromatosis, Gastroenterology, vol.110, pp.1107-1119, 1996.

V. J. Desmet and T. Roskams, Cirrhosis reversal: a duel between dogma and myth, J Hepatol, vol.40, pp.860-867, 2004.

A. L. Fracanzani, S. Fargion, and R. Romano, Portal hypertension and iron depletion in patients with genetic hemochromatosis, Hepatology, vol.22, pp.1127-1131, 1995.

T. Poynard, J. Mchutchison, and M. Manns, Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C, Gastroenterology, vol.122, pp.1303-1316, 2002.

G. V. Papatheodoridis, K. Petraki, and E. Cholongitas, Impact of interferon-alpha therapy on liver fibrosis progression in patients with HBeAg-negative chronic hepatitis B, J Viral Hepat, vol.12, pp.199-206, 2005.

M. C. Rousselet, S. Michalak, and F. Dupre, Sources of variability in histological scoring of chronic viral hepatitis, Hepatology, vol.41, pp.257-64, 2005.

A. Regev, M. Berho, and L. J. Jeffers, Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection, Am J Gastroenterol, vol.97, pp.2614-2622, 2002.

J. Serpaggi, F. Carnot, and B. Nalpas, Direct and indirect evidence for the reversibility of cirrhosis, Hum Pathol, vol.37, pp.1519-1545, 2006.

S. U. Kim, H. J. Oh, and I. R. Wanless, The Laennec staging system for histological subclassification of cirrhosis is useful for stratification of prognosis in patients with liver cirrhosis, J Hepatol, vol.57, pp.556-63, 2012.

C. E. Ruhl and J. E. Everhart, Elevated serum alanine aminotransferase and gammaglutamyltransferase and mortality in the United States population, Gastroenterology, vol.136, pp.477-85, 2009.

S. Patel, R. Jinjuvadia, and R. Patel, Insulin Resistance is Associated With Significant Liver Fibrosis in Chronic Hepatitis C Patients: A Systemic Review and Meta-Analysis, J Clin Gastroenterol, vol.50, pp.80-84, 2016.

M. J. Wood, L. W. Powell, and J. L. Dixon, Clinical cofactors and hepatic fibrosis in hereditary hemochromatosis: the role of diabetes mellitus, Hepatology, vol.56, pp.904-915, 2012.

G. N. Ioannou, M. F. Splan, and N. S. Weiss, Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis, Clin Gastroenterol Hepatol, vol.5, pp.1-4, 2007.

P. Nahon, V. Bourcier, and R. Layese, Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications, Gastroenterology, vol.152, pp.142-156, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01447065

A. C. Cardoso, R. Moucari, and C. Figueiredo-mendes, Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis, J Hepatol, vol.52, pp.652-659, 2010.